IM Cannabis Corp. (NASDAQ:IMCC – Get Free Report) was the recipient of a large decrease in short interest in the month of February. As of February 13th, there was short interest totaling 19,228 shares, a decrease of 38.0% from the January 29th total of 30,993 shares. Currently, 0.3% of the shares of the company are short sold. Based on an average daily trading volume, of 38,381 shares, the days-to-cover ratio is presently 0.5 days. Based on an average daily trading volume, of 38,381 shares, the days-to-cover ratio is presently 0.5 days. Currently, 0.3% of the shares of the company are short sold.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of IM Cannabis in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has a consensus rating of “Sell”.
Get Our Latest Stock Report on IM Cannabis
Institutional Trading of IM Cannabis
IM Cannabis Stock Down 5.8%
IMCC opened at $0.68 on Friday. The firm’s 50 day simple moving average is $1.26 and its two-hundred day simple moving average is $1.63. The company has a market capitalization of $4.01 million, a PE ratio of -0.87 and a beta of 2.10. IM Cannabis has a 1-year low of $0.68 and a 1-year high of $7.12. The company has a current ratio of 0.82, a quick ratio of 0.56 and a debt-to-equity ratio of 0.25.
About IM Cannabis
IM Cannabis Corp is a vertically integrated medical cannabis company based in Israel, specializing in the research, cultivation and production of cannabis-based formulations. The company holds three key licenses granted by the Israeli Ministry of Health, covering cultivation, possession and distribution of medical-grade cannabis. Its production facilities in Moshav Yizrael feature controlled-environment agriculture chambers designed to deliver consistent, high-purity cannabinoid profiles.
The company’s product portfolio includes standardized cannabis oils, distillates, vaporizer cartridges and topical preparations, all formulated under Good Manufacturing Practice (GMP) standards.
Further Reading
- Five stocks we like better than IM Cannabis
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
- Unlocked: Elon Musk’s Next Big IPO
- Buffett, Gates and Bezos Quietly Dumping Stocks—Here’s Why
- Read this or regret it forever
- Silver paying 20% dividend. Plus 68% share gains
Receive News & Ratings for IM Cannabis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IM Cannabis and related companies with MarketBeat.com's FREE daily email newsletter.
